<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03193931</url>
  </required_header>
  <id_info>
    <org_study_id>AIO-KHT-0115</org_study_id>
    <nct_id>NCT03193931</nct_id>
  </id_info>
  <brief_title>Study Comparing Pembrolizumab With Methotrexate in Elderly, Frail or Cisplatin-ineligible Patients With Head and Neck Cancers</brief_title>
  <acronym>ELDORANDO</acronym>
  <official_title>A Randomized Phase II Study Comparing Pembrolizumab With Methotrexate in Elderly, Frail or Cisplatin-ineligible Patients With Head and Neck Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AIO-Studien-gGmbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AIO-Studien-gGmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed as an open-label, randomized, prospective, multicenter, phase II study&#xD;
      comparing pembrolizumab with methotrexate in elderly, frail or cisplatin-ineligible patients&#xD;
      with squamous carcinoma of the head and neck (HNSCC)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 2, 2018</start_date>
  <completion_date type="Anticipated">September 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients recieve pembrolizumab or methotrexate</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>opern label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Antitumor activity of pembrolizumab in SCCHN</measure>
    <time_frame>1 year</time_frame>
    <description>Overall survival (OS) rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life QLQC30 [EORTC QLQ-C30]</measure>
    <time_frame>through study completion, an average of 6 years</time_frame>
    <description>QLQC30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life HN35 [EORTCQLQ-H&amp;N35]</measure>
    <time_frame>through study completion, an average of 6 years</time_frame>
    <description>HN35</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predictive biomarkers</measure>
    <time_frame>through study completion, an average of 6 years</time_frame>
    <description>molecular-genetic pro-inflammatory markers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predictive biomarkers</measure>
    <time_frame>through study completion, an average of 6 years</time_frame>
    <description>PD-L1 expression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to failure of strategy (TTFS)</measure>
    <time_frame>1 year</time_frame>
    <description>defined as death, progressive disease (PD), treatment discontinuation ( or deterioration of Instrumental Activities of Daily Living (IADL score) by 2 points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of pembrolizumab in SCCHN</measure>
    <time_frame>through study completion, an average of 6 years</time_frame>
    <description>Objective response rate (ORR) according to RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>through study completion, an average of 6 years</time_frame>
    <description>Adverse event rates due to treatment with MTX and pembrolizumab in SCCHN measured according to CTCAE 4.03</description>
  </secondary_outcome>
  <other_outcome>
    <measure>QoL response QLQC30</measure>
    <time_frame>through study completion, an average of 6 years</time_frame>
    <description>improvement in QLQC30</description>
  </other_outcome>
  <other_outcome>
    <measure>QoL response HN35</measure>
    <time_frame>through study completion, an average of 6 years</time_frame>
    <description>improvement in HN35</description>
  </other_outcome>
  <other_outcome>
    <measure>prognostic value of tumor shrinkage</measure>
    <time_frame>through study completion, an average of 6 years</time_frame>
    <description>objective response rate (ORR) according to RECIST 1.1</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Cancer of Head and Neck</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pembrolizumab 200 mg q3w i.v. until disease progression or non-tolerable toxicity (maximum 2 years)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm B: Methotrexate (MTX) 40 mg/m2 weekly i.v. until disease progression or non-tolerable toxicity (maximum 2 years)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab Injection</intervention_name>
    <description>Pembrolizumab 200 mg q3w i.v. until disease progression or non-tolerable toxicity (maximum 2 years)</description>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate Injectable Solution</intervention_name>
    <description>Methotrexate 40 mg/m2 weekly i.v. until disease progression or non-tolerable toxicity (maximum 2 years)</description>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Cooperation and willingness to complete all aspects of the study&#xD;
&#xD;
          2. Signed written informed consent must be given prior to study inclusion&#xD;
&#xD;
          3. Histological or cytological confirmed recurrent or metastatic squamous cell carcinoma&#xD;
             of the head and neck (HNSCC) not amenable to local therapies&#xD;
&#xD;
          4. Progressive disease at study entry&#xD;
&#xD;
          5. At least 1 measurable lesion according to RECIST 1.1&#xD;
&#xD;
          6. No previous systemic treatment for metastatic disease&#xD;
&#xD;
          7. Not eligible for cisplatin-based chemotherapy, defined as:&#xD;
&#xD;
               -  ECOG 2 [Eastern Cooperative Oncology Group] and/or&#xD;
&#xD;
               -  Calculated CrCl [Creatinine Clearance] &lt;60 mL/min (measured by MDRD)&#xD;
&#xD;
          8. Age ≥ 18 years&#xD;
&#xD;
          9. ECOG performance status 0 - 2&#xD;
&#xD;
         10. Brain metastases require completion of local therapy with discontinuation of steroids&#xD;
             prior to start of treatment&#xD;
&#xD;
         11. If of childbearing potential, willingness to use highly effective contraceptive method&#xD;
             for the duration of the study and 120 days after last dose, such as combined (estrogen&#xD;
             and progestogen containing) hormonal contraception associated with inhibition of&#xD;
             ovulation, progestogen-only hormonal contraception associated with inhibition of&#xD;
             ovulation, intrauterine device (IUD), intrauterine hormone-releasing system (IUS),&#xD;
             vasectomized partner, bilateral tubal occlusion, sexual abstinence. If an oral&#xD;
             contraception is used, a barrier method of contraception (e.g. male condom, female&#xD;
             condom, cervical cap, diaphragm, contraceptive sponge) has to be applied additionally.&#xD;
&#xD;
         12. Adequate bone marrow function, liver and renal function:&#xD;
&#xD;
               1. Absolute neutrophil count ≥ 1.5 x 109/L&#xD;
&#xD;
               2. Thrombocytes ≥ 100 x 109/L&#xD;
&#xD;
               3. Hemoglobin ≥ 9 g/dL&#xD;
&#xD;
               4. INR [international normalized ratio] ≤ 1.5 and PPT [partial prothrombin time] ≤&#xD;
                  1.5 x lower limit during the last 7 days before therapy&#xD;
&#xD;
               5. Bilirubin &lt; 1.5 x lower limit and&#xD;
&#xD;
               6. AST (GOT) [aspartate aminotransferase] and ALT (GPT) [alanine transaminase] &lt; 3 x&#xD;
                  lower limit (5 x lower limit in case of liver metastases)&#xD;
&#xD;
         13. Tumor block or 20 slides must be available at study inclusion for central pathology&#xD;
             testing&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Live expectancy less than 3 months&#xD;
&#xD;
          2. Nasopharynx carcinoma&#xD;
&#xD;
          3. Anticancer treatment during the last 30 days prior to start of treatment, including&#xD;
             systemic therapy, radiotherapy or major surgery&#xD;
&#xD;
          4. Participation in a clinical trial within the last 30 days prior to study treatment&#xD;
&#xD;
          5. History of allogeneic tissue/solid organ transplant&#xD;
&#xD;
          6. History of pneumonitis that has required oral or i.v. steroids&#xD;
&#xD;
          7. Evidence of interstitial lung disease&#xD;
&#xD;
          8. Minor surgery ≤ 24 hours prior first dose of study treatment&#xD;
&#xD;
          9. Symptomatic acute cardiovascular or cerebrovascular disease&#xD;
&#xD;
         10. Known active HBV [hepatitis B virus], HCV [hepatitis C virus] or HIV infection&#xD;
&#xD;
         11. Has any other active infection requiring systemic therapy.&#xD;
&#xD;
         12. Patients with active tuberculosis&#xD;
&#xD;
         13. Prior therapy with an anti-Programmed cell death protein 1 (anti-PD-1), anti-PD-L1,&#xD;
             anti-Programmed cell death-ligand 2 (anti-PD-L2), anti-CD137 (4-1BB ligand, a member&#xD;
             of the Tumor Necrosis Factor Receptor (TNFR) family), or anti-Cytotoxic&#xD;
             T-lymphocyte-associated antigen-4 (anti-CTLA-4) antibody (including ipilimumab or any&#xD;
             other antibody or drug specifically targeting T-cell co-stimulation or checkpoint&#xD;
             pathways)&#xD;
&#xD;
         14. A diagnosis of immunodeficiency or patient is receiving chronic systemic steroid&#xD;
             therapy or any other form of immunosuppressive therapy within 7 days prior to the&#xD;
             first dose of trial treatment.&#xD;
&#xD;
         15. Patient has had a prior monoclonal antibody, which does significantly interfere with&#xD;
             the immune system or which does have a systemic therapeutic effect on the tumor within&#xD;
             4 weeks prior to randomization.&#xD;
&#xD;
         16. Patient has not recovered (i.e., ≤ Grade 1 or at baseline) from any toxicity due to&#xD;
             agents administered more than 4 weeks earlier. [Subjects with ≤ Grade 2 neuropathy or&#xD;
             alopecia are an exception to this criterion and may qualify for the study.]&#xD;
&#xD;
         17. Has an active autoimmune disease requiring systemic treatment within the past 3 months&#xD;
             or a documented history of clinically severe autoimmune disease, or a syndrome that&#xD;
             requires systemic steroids or immunosuppressive agents. Subjects with vitiligo or&#xD;
             resolved childhood asthma/atopy would be an exception to this rule. Subjects that&#xD;
             require intermittent use of bronchodilators or local steroid injections would not be&#xD;
             excluded from the study. Subjects with hypothyroidism stable on hormone replacement or&#xD;
             Sjorgen's syndrome will not be excluded from the study.&#xD;
&#xD;
         18. Has received a live vaccine within 30 days prior to the first dose of trial treatment.&#xD;
&#xD;
         19. Has known hypersensitivity to methotrexate or pembrolizumab or any constituent of the&#xD;
             products..&#xD;
&#xD;
         20. Other active malignancy requiring treatment&#xD;
&#xD;
         21. Lactating or pregnant women, women of child-bearing potential who do not agree to the&#xD;
             usage of highly effective contraception methods (allowed methods of contraception,&#xD;
             meaning methods with a rate of failure of less than 1% per year are combined (estrogen&#xD;
             and progestogen containing) hormonal contraception associated with inhibition of&#xD;
             ovulation, progestogen-only hormonal contraception associated with inhibition of&#xD;
             ovulation, intrauterine device (IUD), intrauterine hormone-releasing system (IUS),&#xD;
             vasectomized partner, bilateral tubal occlusion, sexual abstinence. If an oral&#xD;
             contraception is used, a barrier method of contraception (e.g. male condom, female&#xD;
             condom, cervical cap, diaphragm, contraceptive sponge) has to be applied&#xD;
             additionally). Women of childbearing potential must have a negative pregnancy test&#xD;
             (serum β-hCG) at Screening.&#xD;
&#xD;
         22. Any psychiatric illness that would affect the patient's ability to understand the&#xD;
             demands of the clinical trial&#xD;
&#xD;
         23. Patient has already been recruited in this trial (does not include screening failures)&#xD;
&#xD;
         24. Patient who has been incarcerated or involuntarily institutionalized by court order or&#xD;
             by the authorities § 40 Abs. 1 S. 3 Nr. 4 AMG.&#xD;
&#xD;
         25. Patients who are unable to consent because they do not understand the nature,&#xD;
             significance and implications of the clinical trial and therefore cannot form a&#xD;
             rational intention in the light of the facts [§ 40 Abs. 1 S. 3 Nr. 3a AMG].&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Medizinsche Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 31, 2017</study_first_submitted>
  <study_first_submitted_qc>June 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 21, 2017</study_first_posted>
  <last_update_submitted>June 29, 2020</last_update_submitted>
  <last_update_submitted_qc>June 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

